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Transformed plasma cells in multiple myeloma (MM) are susceptible to natural killer (NK) cell-mediated killing via 
engagement of tumor ligands for NK activating receptors or “missing-self” recognition. Similar to other cancers, MM 
targets may elude NK cell immunosurveillance by reprogramming tumor microenvironment and editing cell surface 
antigen repertoire. Along disease continuum, these effects collectively result in a pro- gressive decline of NK cell 
immunity, a phenomenon increasingly recognized as a critical determinant of MM progression. In recent years, 
unprecedented efforts in drug devel- opment and experimental research have brought about emergence of novel 
therapeutic interventions with the potential to override MM-induced NK cell immunosuppression. These NK-cell 
enhancing treatment strategies may be identified in two major groups: (1) immunomodulatory biologics and small 
molecules, namely, immune checkpoint inhibi- tors, therapeutic antibodies, lenalidomide, and indoleamine 2,3-
dioxygenase inhibitors and (2) NK cell therapy, namely, adoptive transfer of unmanipulated and chimeric anti- gen 
receptor-engineered NK cells. Here, we summarize the mechanisms responsible for NK cell functional suppression 
in the context of cancer and, specifically, myeloma. Subsequently, contemporary strategies potentially able to 
reverse NK dysfunction in MM are discussed. 
Keywords: multiple myeloma, immunotherapy, natural killer cells, killer immunoglobulin-like receptors, cytokines, immune checkpoint inhibition, 
daratumumab, elotuzumab, iDO inhibitors, chimeric antigen receptor 
 
iNTRODUCTiON 
Multiple myeloma (MM) is a B-cell malignancy characterized by an abnormal growth of malignant plasma cells which derive from a 
post-germinal B-cell of the lymphoid cell lineage. The treatment paradigm for MM has undergone a dramatic evolution in the past 
decade given a considerable improvement in the understanding of disease pathogenesis. Despite the development of novel therapeutic 
agents such as proteasome inhibitors—bortezomib, carlfizomib—and immunomodu- latory drugs—lenalidomide, pomalidomide—
which target not only MM cells but also their inter- play with the microenvironment, MM remains an incurable disease and the 
prognosis of patient with relapsed/refractory MM remains  very  poor.  A  number of factors concur to make MM a hard-to-treat 
hematologic malignancy. Drug resistance  remains  a  major  concern.  MM is a highly heterogeneous disease with pathogenic 
processes that may greatly differ among newly diagnosed patients and others that may arise during the disease course. In recent years, 
several studies have focused on mechanisms of drug resistance even though many are not yet completely understood. It is widely 
assumed that cytogenetic and epigenetic abnormalities, deregulated signaling pathways, the MM bone marrow (BM) 
microenvironment, and the MM stem cell itself are all elements which play significant roles in drug resistance. Deletion 17p13 is one 
of the most relevant chromosomal abnormalities present in approximately 10–15% of newly diagnosed patients and observed more 
frequently in refractory-relapsed patients. It has been associated with resistance to new agents such as bortezomib and lenalidomide (1, 
2). Aberrant drug transport processes and anti-apoptosis mechanisms have also been correlated with drug resistance (3, 4). Moreover, a 
pivotal role is played by the intense cell–cell crosstalk between the BM microenvironment and MM cells and their interplay with the 
extracellular matrix (5). All  the abovementioned mechanisms make MM very challenging to eradicate with single-agent or 
combination modalities. Thus, an urgent need exists for new therapeutic strategies to overcome resistance to current therapies. MM is 
also characterized by a gradual and progressive immune dysregulation with impairs functions of B and T cell immunity, natural killer 
(NK) cells, and antigen-presenting/dendritic cells that allow malignant plasma cells to escape immunosurveillance. The combination  
of an “immunosuppressive” microenvironment and clonal evolution activate signaling pathways that invariably promote disease 
survival and progression. Several immunotherapies have recently been proposed and, among others, they have included monoclonal 
 antibodies, antibody–drug conjugates, chimeric antigen receptor T cell therapy (CAR-T cells), tumor vaccines, and immune 
checkpoint inhibitors. This review provides an overview of the biological functions and potential clinical role of NK cells as a form of 
immunotherapy that may improve MM clinical outcomes. 
 
PHYSiOLOGY OF NK CeLLS AND THeiR ReCePTORS 
Missing-Self Recognition and inhibitory NK Cell Receptors 
In the early 1970s, immune effectors isolated from mice and humans were found to display in vitro antitumor cytotoxicity without 
prior immunization by tumor antigens in vivo (6–9). These cells were functionally defined as N-cells or NK cells and were believed 
to belong to the lymphoid lineage, but to be distinct from B and T cells (10–13). Mechanisms regulating  NK cell-mediated target 
recognition and killing remained obscure for more than a decade after natural cytotoxicity was first described. In 1986, Karre et al. 
reported that resistance     of mice lymphoma cells to NK cell-mediated rejection was dependent on major histocompatibility 
complex (MHC) class 
I antigen expression on cancer surface (14). This observation led to the assumption that NK cell would possess receptors able to 
transduce negative signals upon MHC class I engagement, thus sparing putative targets. Lack of MHC class I would instead trigger 
NK cell activation, a phenomenon known as missing-self recognition (15). 
In humans, the NK cell inhibitory receptors able to recognize HLA class I are type I transmembrane structures belonging to the 
immunoglobulin (Ig) superfamily, known as killer immu- noglobulin-like receptors (KIR). Inhibitory KIR share a long 
(L) cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motifs that can process signals through the recruit- ment 
and activation of the SH2-domain-containing tyrosine phosphatase 1 protein (16–20). Three inhibitory KIR engaging HLA class I 
ligand groups are critical regulators of NK cell func- tion: KIR2DL1, specific for HLA-C2 group antigens (sharing Asn at position 77 
and Lys at position 80 of the HLA-Cw heavy chain); KIR2DL2/3, specific for HLA-C1 group antigens (sharing Ser at position 77 and 
Asn at position 80 of the HLA-Cw heavy chain) (21, 22); and KIR3DL1, specific for the HLA-Bw4 epitope (located at position 77–83 
of the heavy chain of certain HLA-B and HLA-A alleles) (23–25). 
In the last  two  decades,  multiple  additional  inhibitory  NK cells receptors have been identified, leading to the currently 
accepted notion that NK cell effector function is dependent on the overall balance of signals transduced by multiple inhibitory and 
activating receptors recognizing cognate ligands on virally infected and cancer cells. Examples of non-KIR inhibitory NK receptors 
include the c-type lectin-like CD94/NKG2A (CD159a) heterodimer and ILT2 (LILRB1, CD85j), respectively, engaging HLA-E and 
various HLA class I antigens (26, 27); NKR-P1A (CD161) recognizing the lectin-like transcript 1 (28, 29); and the 
carcinoembryonic antigen-related cell adhesion molecule 1 (CD66a) recognizing the CD66 ligand (30–32). 
Activating NK Cell Receptors 
Activating NK cell receptors are also described. Among them, NKG2D (CD314) has ligand specificity for a wide range of stress-
induced cell surface ligands (NKG2D-L), including the MHC-related ligands MICA and MICB (33) and the human 
cytomegalovirus glycoprotein (UL16)-binding proteins ULBP1-6 (33, 34). Natural cytotoxicity receptors (NCRs) NKp46 (NCR1, 
CD335) (35, 36), NKp44 (NCR2, CD336) (37), and NKp30 (NCR3, 
CD337) (38) are potent activating receptors almost exclusively restricted to NK cells. Ligands for NCR are currently incompletely 
characterized. NKp46 and NKp44 are known to bind several viral hemagglutinins (39, 40), while NKp30 recognizes the HLA-B- 
associated transcript 3 (BAT3) (41) and B7-H6, a member of the B7 immunoreceptor family (42). CD94/NKG2C (CD159c) binds the 
non-classical HLA-E, similar to its inhibitory CD94/NKG2A counterpart (25). CD16 (FcγRIIIA) (43) is the low-affinity IgG 
receptor, strongly expressed on mature NK cells, mediating antibody-dependent cellular cytotoxicity (ADCC) (44). Other important 
activating receptors include the SLAM-related 2B4 (CD244) (45) engaging the pan-leukocyte surface antigen CD48 
(46) and the adhesion molecule DNAM-1 (47) involved in recog- nition of PVR (CD155) and nectin-2 (CD112) (48
  
NK CeLL iMMUNiTY DYSFUNCTiON iN MM 
Tumor-induced Microenvironment Transformation 
Accumulating evidence indicates that microenvironment transformation may significantly impair NK cell effector func- tion in MM 
(49). Plasma cells and T regulatory (Treg) cells from patients with MM secrete high levels of TGF-β (50, 51), a potent 
immunosuppressive cytokine known to downregulate multiple NK-activating receptors and to impair NK cytotoxicity (52–54). IL-10 
and IL-6 are increased in MM (55–57) and independently act as powerful growth factors for malignant plasma cells (58, 59). IL-10 
inhibits production of pro-inflammatory IFN-γ and TNF-α (60, 61) and promotes development of NK-resistant tumor phenotypes 
(62), although it may also enhance NK cytotoxicity in response to IL-15 exposure in vitro (63). IL-6 has been shown to impair NK 
cell activity in experimental models, human disease, and when administered to patients with advanced cancer (64–66). Altered levels 
of IFN-γ may also contribute to NK cell dysregulation in MM. In two studies, serum IFN-γ levels were found to be significantly lower 
in subjects with MM than in normal controls (55, 56), potentially affecting NK cell activity. Besides cytokines, other soluble factors 
are known to suppress NK-mediated antitumor capabilities. Prostaglandin E2 inhibits activating signals transduced by NCR, 
NKG2D, and CD16 (67) and has been shown to be actively produced in cultures of BM from patients with MM (68). Indoleamine 2,3-
dioxygenase (IDO) promotes cancer cell immune escape through potent immu- noregulatory effects on antigen-presenting cells via 
enzymatic degradation of l-tryptophan (69) (see IDO inhibitors). Della Chiesa et al. described that IDO-mediated 
immunosuppression also involves NK cells via l-kyreunine (Kyn), a l-tryptophan (Trp) degradation product impairing 
NKp46/NKG2D-specific lysis (70). Interestingly, interaction between CD28 on MM cells and CD80/86 stimulates IDO production 
by stromal dendritic cells (71), in agreement with the observation that CD28 expres- sion on MM plasma cells is a marker correlating 
with poor disease outcome (72). 
Additional microenvironmental factors may contribute to blunted NK cell cytotoxicity and cytokine production in MM. Among 
them, myeloid-derived suppressor cells (MDSCs) have been found to be expanded in MM (73, 74) and to directly contribute to 
downregulation of NK cell responsiveness via the NKp30-activating receptor (75), membrane-bound TGF-β (76), and TIGIT-
mediated inhibitory signaling (77). Furthermore, reduced oxygenation described in MM BM (78, 79) may inhibit NK cell anti-
myeloma responsiveness (80). 
 
effect of Soluble Ligands on NK Cell-Mediated immunity in MM 
MICA and MICB (collectively named MIC) are stress-inducible NKG2D ligands frequently overexpressed in response to malig- nant 
transformation (81). When bound to tumor surface, they act as markers of “abnormal self ” and may trigger NK cell cytotoxicity via 
NKG2D signaling. Conversely, cleavage of membrane-bound MIC is a strategy employed by MM  and other tumors to evade NK 
cell immunosurveillance (82–85).   In individuals with MIC+ tumors, soluble MIC (sMIC) ligands induce internalization of surface 
NKG2D (but also NCR and chemokine receptors) and substantial impairment of NK effec- tor functions (86–88). In addition, sMIC 
has been shown to promote the accumulation of MDSC and macrophages with an immunosuppressive phenotype (89), potentially  
contributing  to NK cell suppression. Not surprisingly, presence of sMIC is associated with poor cancer survival (90–92). In MM, 
shedding of MIC may result from exposure of MM cells to the genotoxic agents, doxorubicin and melphalan (93). Proteolytic 
cleavage by ADAMTS10 has been described to mediate this phenomenon, suggesting that the combination of metalloproteinase 
inhibitors with chemotherapy would exert a protective effect against escape of MM cells from NK-mediated recognition (93). Similar 
to NKG2D-L, NCR-specific soluble ligands may in some instances induce NK cell functional impairment. For example, circulat- ing 
BAG6/BAT3 may inhibit NK cell cytotoxicity by inducing NKp30-specific hyporesponsiveness (94). Shedding of these ligands in 
the context of MM has not been investigated. 
effect of Cell Contact on NK Cell-Mediated immunity in MM 
Derangement of NK cell effector functions may be further amplified by tumor ligand surface expression patterns favoring 
dominance of inhibitory NK signals. Ligands recognized by NK-activating receptors are often poorly expressed in cancer. 
Downregulation of membrane-bound  NKG2D-L  is  common in multiple tumors, resulting in impaired NKG2D-dependent NK cell 
cytotoxicity (95–97) and unfavorable clinical outcomes (97). In the context of monoclonal gammopathy, expression of MICA is 
known to decrease upon transition from pre-cancerous monoclonal gammopathy of undetermined significance (MGUS) to MM (84). 
Of note, various pharmacological interventions may counter NKG2D-L downregulation in MM: vincristine, via p38 MAPK pathway 
activation (98); doxorubicin, melphalan, and bortezomib as a result of oxidative stress, DNA damage, and tumor senescence (99, 
100) the heat shock protein-90 (HSP90) chaperone protein inhibitors 17-allylaminogeldanamycin and radicicol (101); and inhibition 
or degradation of bromodomain and extra-terminal proteins (102). Exposure to therapeutic agents with activity on MM has similarly 
been shown to induce upregu- lation of PVR (an activating ligand for DNAM-1) on malignant plasma cells (98, 100, 103). Besides 
NKG2D-L, surface expression of the B7-H6 ligand, engaging the NKp30 NCR, has been found to be downregulated in cell lines 
generated from multiple cancers, including MM, resulting in NKp30-dependent NK cell functional impairment (104). 
Upregulation of tumor-bound HLA class I antigens is another mechanism of protection against NK cell immunosurveillance. 
Malignant plasma cells obtained from the BM of early-stage myeloma patients display low HLA class I expression potentially 
favoring NK-mediated killing (105). In contrast, high HLA class I levels are observed on plasma cells derived from pleural effusions of 
patients with advanced MM (105). HLA-E is a non-classical 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FiGURe 1 | (A) Antitumor cytotoxic activity of NK cells in healthy individuals 
is not impaired by PD-1 expression. (B) NK cells from MM patients express 
PD-1, which promotes MM escape from NK cell-mediated 
immunosurveillance upon engagement with cognate ligand PD-L1 on plasma 
cells. PD-1/PD-L1 blocking monoclonal antibodies may potentiate NK cell 
effector functions against MM. NK, natural killer; PD-1, programmed death 
receptor-1; MM, multiple myeloma. 
 
HLA class I antigen frequently upregulated on cancer cells, a 
phenomenon correlating with poor prognosis (106). In MM pri- 
mary cells, high HLA-E expression results in restrained in vitro 
degranulation of NK cell subsets expressing the HLA-E-specific 
inhibitory NK receptor NKG2A (107). 
Surface overexpression of ligands for inhibitory NK receptors 
is not restricted to HLA class I antigens. Notably, the CD200 
glycoprotein is also commonly overexpressed on cancer surface, 
specifically in myeloid and lymphoid leukemias, where it is a 
marker of poor prognosis (108, 109). Leukemia blasts overex- 
pressing CD200 escape NK-mediated immunosurveillance by 
dampening NK cell cytolytic capabilities and NKp44/NKp46 
receptor expression (110), a phenomenon that can be reversed 
by CD200 blockade (111). CD200 is also frequently expressed in 
patients with MM, where it adversely affects clinical outcomes 
following stem cell transplantation (112). 
 
Numerical, Phenotypic, and Functional 
Characteristics of NK Cells in MM 
Multiple reports describe numerical, phenotypic, and functional 
NK cell alterations in MM. Subjects with MGUS and untreated, 
early-stage MM have been generally found to have higher (113– 
115) or similar (116–118) numbers of circulating and BM NK cells 
than healthy donors. Upregulation of CD57 and CD16 on NK cell 
surface is also observed (119, 120), suggesting the emergence of 
terminally differentiated subsets with high-cytotoxic potential. 
While these findings suggest efficient response to malignant 
clones subject to NK-mediated immunosurveillance, several lines 
of evidence favor the view that such early anti-MM effects are 
rather to be interpreted as a sign of immunological stress resulting 
in poor disease control. In fact, the effector function of expanded 
NK cells from MM subjects has been unexpectedly found to be 
similar to that of NK cells obtained from healthy donors (114), 
and NK cells obtained from untreated or previously treated MM 
patients show a lower increase in cytotoxicity to the K562 cell 
line in response to pre-incubation with IFN-γ (121). Moreover, 
NK cell effector functions positively correlate with presence of 
adverse prognostic factors, including anemia, low albumin, high 
β2-microglobulin, and renal failure (115), suggesting a “stressed” 
immunoresponse under the pressure of an aggressive clonal 
expansion (115). Notably, NK cells from patients with MM display 
an “exhausted” phenotype signature that includes downregulation 
of multiple activating receptors and upregulation of programmed 
death receptor-1 (PD-1). Surface expression of activating 2B4 is 
reduced in both PB (122) and BM (123) NK cells obtained from 
untreated subjects with MM, potentially preventing killing of 
plasma cells despite low HLA class I expression (105). NKG2D 
and NCR are also downregulated in MM, but preferentially in the 
BM (122, 123), supporting the concept that downregulation of 
certain activating NK cell receptors is both dependent on soluble 
ligands and direct cell–cell contact. Negative signaling from PD-1 
is a well-established marker of exhaustion on T cells, but can also 
disrupt NK cell cytotoxicity and cytokine production (124). In 
MM, both expression of PD-1 on NK cells and of its ligand PD-L1 
on plasma cells has been described (125, 126). PD-1/PD-L1 inter- 
actions may therefore promote NK cell functional exhaustion 
in MM, a phenomenon potentially reversible by checkpoint 
blockade inhibition (see Inhibitors of the PD-1/PD-L1 Pathway; 
Figure 1). 
Natural killer cell-mediated immunity  further  deteriorates 
in advanced MM. Compared to MGUS and untreated MM, PB 
NK cell numbers are substantially reduced in advanced disease 
(113). Altered distribution of NK cell subsets in human BM may 
be likewise hypothesized based on studies in mice demonstrating 
selective decrease of KLRG1− NK cells during MM progression 
(127). Evolving phenotype editing further promotes tumor escape 
from NK cell-mediated immunosurveillance. Furthermore, the 
activating receptor DNAM-1, expressed on NK cells from healthy 
donors and with MM in complete remission, is downregulated on 
NK cells from patient with active MM (128). This phenomenon is 
particularly relevant for late-stage cancer immune escape, as kill- 
ing of malignant plasma cells is in certain circumstances critically 
dependent on DNAM-1 engagement of PVR and nectin-2 (128, 
129). In line with these findings, NK cell activity in advanced 
MM is significantly impaired (130). Taken together, these data 
 
  
 
indicate that NK cell immunity alterations, already detectable in 
early myeloma, progress in a clinical stage-dependent manner 
and that immunotherapy modalities based on efficient NK cell 
effector function such as (i.e., mAbs) are likely to exert a more 
effective anti-myeloma effect when used in early-stage disease. 
Factors promoting NK immunity suppression in MM are 
summarized in Table 1. 
 
iMMUNe CHeCKPOiNT BLOCKADe 
OF NK CeLLS 
inhibitors of the PD-1/PD-L1 Pathway 
Programmed death receptor-1 is a transmembrane protein 
expressed on the surface of antigen-activated T and B cells. It has 
two ligands, PD-L1 and PD-L2. PD-L1 is expressed on both anti- 
gen-presenting cells/dendritic cells and a wide spectrum of non- 
hematopoietic cells. PD-1/PD-L1 interactions physiologically 
counter T cell stimulatory signals and allow T cell homeostasis 
and self-tolerance by suppressing activation and proliferation of 
autoreactive T cells. PD-1/PD-L1 binding delivers an inhibitory 
costimulatory signal that induces a state of T cell exhaustion that 
prevents activation and proliferation of T cells. Unlike NK cells 
from healthy donors, NK cells from MM patients express PD-1 
(Figure 1A), suggesting that NK cells from healthy donors do not 
express PD-1 (Figure 1A), however, NK cells from MM patients 
do. This may show that a functional change in NK cells in response 
to MM may cause an immunosuppressive microenvironment for 
MM to grow. In the light of these observations and the broad 
expression of PD-1 and its ligands in the MM microenvironment, 
the PD-1/PD-L1 pathway may play a pivotal role in the immune 
evasion of MM cells (Figure 1B). 
A role for the PD-1/PD-L1 signaling pathway in the NK cell 
immunoresponse against MM and of the anti-PD1 antibody CT-
011 was first shown by Benson et al. (125). CT-011 was 
demonstrated to enhance human NK cell function against 
autologous, primary MM cells by affecting NK cell trafficking, 
immune complex formation with MM cells, and cytotoxicity 
toward MM cells expressing PD-L1 while sparing normal cells 
(Figure 1B). 
It was also shown that lenalidomide had the ability to down 
regulate PD-L1 on primary MM cells and, by so doing, increase 
NK cell functions against MM. Thus, targeting the PD-1/PD-L1 
pathway may become a feasible clinical strategy in MM, especially 
in patients with persistent residual disease (131). 
One preliminary phase I study reported on 17 patients treated 
with pembrolizumab, a PD-1 inhibitor, in combination with 
lenalidomide and dexamethasone (132). Overall response and 
very good partial response rates were 76 and 23%, respectively. 
Some 75% of patients achieved stable disease. Many patients were 
 
 
 
 
TABLe 1 | Microenvironment alterations potentially promoting natural killer (NK) immunity suppression in multiple myeloma. 
 
Factors Function effect of TM impact on NK cell immunity Reference 
Soluble     
TGF-β Anti-inflammatory cytokine ⇑ Reduced NK effector functions 
Downregulation of activating receptors 
Castriconi et al. (52); Lee et al. (53); 
Mamessier et al. (54) 
IL-10 Anti-inflammatory cytokine ⇑ Resistance to NK cytotoxicity 
Reduced NK cytokine production 
Tsuruma et al. (62); Sharma et al. (55); 
Zheng et al. (56) 
IL-6 Pro-inflammatory cytokine ⇑ Reduced NK effector functions Bataille et al. (57); Scheid et al. (66) 
IFN-γ Pro-inflammatory cytokine ⇓ Reduced NK effector functions Sharma et al. (55); Zheng et al. (56) 
PGE2 Prostaglandin ⇑ Reduced NK effector functions 
Inhibition of positive intracellular signaling 
Lu et al. (68); Martinet et al. (67) 
sMIC NKG2D ligand ⇑ Reduced NK effector functions 
Downregulation of NK activating receptors 
Groh et al. (86); Jinushi et al. (84); Xiao et al. (89) 
Cell bound     
mMIC NKG2D ligand ⇓ Resistance to NK cytotoxicity Jinushi et al. (84) 
B7-H6 NKp30 ligand ⇓ Resistance to NK cytotoxicity Fiegler et al. (104) 
HLA class I KIR/NKG2A ligands ⇑ Resistance to NK cytotoxicity Carbone et al. (105); Bossard et al. (106); 
Sarkar et al. (107) 
CD200 Membrane glycoprotein ⇑ Reduced NK effector functions 
Downregulation of NK activating receptors 
Moreaux et al. (112); Coles et al. (110) 
2B4 Activating receptor ⇓ Reduced NK effector functions Fauriat et al. (122); Costello et al. (123) 
NKG2D Activating receptor ⇓ Reduced NK effector functions Fauriat et al. (122); Costello et al. (123) 
NCRs Activating receptors ⇓ Reduced NK effector functions Fauriat et al. (122); Costello et al. (123) 
DNAM-1 Activating receptor ⇓ Reduced NK effector functions El-Sherbiny et al. (128) 
PD-1 Immune checkpoint 
receptor 
⇑ Reduced NK effector functions Benson et al. (125); Gorgun et al. (126); 
Beldi-Ferchiou et al. (124) 
KLRG1 Co-inhibitory receptor ⇑ Reduced NK effector functions Ponzetta et al. (127) 
TM, tumor microenvironment; PGE2, prostaglandin E2; sMIC, soluble MIC; mMIC, membrane-bound MIC; KIRs, killer immunoglobulin-like receptors; NCRs, natural cytotoxicity 
receptors; PD-1, programmed cell death protein 1/programmed cell death protein ligand 1; KLRG1, killer cell lectin-like receptor subfamily G member 1. 
⇑ denotes increase; ⇓ denotes decrease. 
  
 
heavily pretreated with other lines of therapy. Almost all patients, 
however, experienced at least one adverse event with anemia, 
neutropenia, thrombocytopenia, fatigue, hyperglycemia, and 
muscle spasms being the most common. Two other recent stud- 
ies with nivolumab showed acceptable toxicity but no objective 
responses (133, 134). Efficacy assessment of nivolumab, alone or 
in combination, is ongoing. 
More recently, a novel subpopulation of human NK cells 
expressing high levels of PD-1 have been identified in ovarian 
cancer, characterized by low proliferative responses, and impaired 
antitumor activity that can be partially restored by antibody- 
mediated disruption of PD-1/PD-L1 interaction (135). 
Future studies to evaluate the real therapeutic role of anti-PD-1 
antibodies, maybe in combination with other agents with potent 
anti-myeloma activity such as lenalidomide, are warranted. 
 
KiR-Specific immune Checkpoint 
inhibition 
The role of NK cells as graft-vs.-myeloma effectors was first 
investigated in preclinical models. Frohn et al. described for the 
first time the killing ability of NK cells against three different MM 
cell lines. The mean NK cell killing ability on MM samples ranged 
from 23 to 34.5% (136). Moreover, KIR-ligand mismatch in T cell- 
depleted allogeneic stem cell transplantation reduced the relapse 
incidence in MM recipients. The impact of KIR-ligand mismatch 
was assessed in a cohort of 73 MM patients who received reduced- 
intensity unrelated donor transplants. KIR-ligand mismatch in 
the graft-vs.-host disease direction was significantly associated 
with lower risk of relapse (HR: 0; p < 0.0001) (137). 
To exploit this pathway, Romagné et al. generated an IgG 
monoclonal antibody, 1-7F9, against three different KIRs 
(KIR2DL-1, KIR2DL-2, and KIR2DL-3) to enhance the NK cells 
antitumor effect. This checkpoint inhibitor augmented NK cell- 
mediated lysis of HLA-C-expressing tumor cells without interfer- 
ing with normal peripheral blood (PB) mononuclear cells (138) 
(Figure 2A). The therapeutic potential of 1-7F9 was then demon- 
strated in preclinical mouse models, providing the platform for 
translational studies in humans (139). 
The drug IPH2101, formerly 1-7F9, was tested in a phase I 
trial in 32 patients with relapsed/refractory MM. IPH2101 was 
administered for up to four 28-day cycles, in 7 dose-escalated 
cohorts (0.0003–3 mg/kg). Only one patient developed severe 
toxicity, characterized by grade 4 acute renal failure with hyper- 
kalemia and hyperuricemia. From a biological point of view, the 
drug determined the full saturation of NK inhibitory KIRs (140). 
Furthermore, lenalidomide and IPH2101 were investigated as a 
novel, steroid-sparing, dual immunotherapy in 15 MM patients: 
the biological endpoint of full KIR occupancy was achieved,    
5 patients had a response, and 5 severe adverse events were 
reported (141). 
In an open-label, single arm two-stage phase II trial, IPH2101 
was employed at the dose of 1 mg/kg every other month for six 
cycles in nine patients with smoldering MM. Despite the prom- 
ising results from preclinical and phase I studies, the trial was 
terminated before planned second stage due to lack of patients 
meeting the primary objective (50% decline in M-protein) (142). 
A recombinant version of IPH2101 was developed with a 
stabilized hinge (lirilumab). A phase I study of the safety and 
tolerability of lirilumab with elotuzumab in myeloma patients  
is currently in progress. Of note, lirilumab recognizes both the 
inhibitory KIR2DL1, -L2, and -L3 and the activating KIR2DS1-2. 
Therefore, lirilumab-mediated modulation of intracellular sig- 
nals is expected to vary according to patient’s HLA class I genetic 
background and KIR receptor repertoire. 
In vitro experiments showed that KIR2D molecules are 
removed from NK cells surface by trogocytosis. This phenom- 
enon culminated in a strong reduction of NK cell cytotoxic func- 
tion correlating with the loss of free KIR2D surface molecules 
(143). These data favor future protocol designs where lirilumab 
is administered in combination with other NK cell-activating 
agents, rather than as single agent. 
 
iMMUNOMODULATORY DRUGS 
AND MONOCLONAL ANTiBODieS 
Lenalidomide 
Lenalidomide, a thalidomide analog, is an immunomodulatory 
drug with multiple mechanisms of action in MM. It is currently 
approved in both EU and USA in association with dexamethasone 
for the maintenance treatment of patients with newly diagnosed 
MMwhohaveundergoneanautograft. Fourpivotalphase III stud- 
ies have associated lenalidomide with improved progression-free 
survival and better overall response rates (144–147). Although 
lenalidomide has also been associated with increased risk of a 
second primary cancer, the overall survival benefits outweigh the 
risk (148). 
Due to failure of single-agent anti-KIRs in phase II studies, 
researchers from multiple institutions investigated possible 
combined therapies. In vitro, the immunomodulatory agent 
lenalidomide was responsible of NK cell expansion and activation 
associated with malignant cells apoptosis (149). On this platform, 
Benson et al. tested the cytotoxicity of IPH2101 in combination 
to lenalidomide against MM cell lines U266 and K562 (139, 
140). Healthy donor NK cells pretreated with lenalidomide or 
IPH2101 alone and combined showed increased IFN-γ produc- 
tion against primary MM cells compared to controls (p < 0.05). 
Furthermore, NK cells pretreated with both lenalidomide and 
IPH2101 led to the highest IFN-γ peak. The statistical interaction 
of p-value was 0.0182, suggesting a synergistic effect between 
the two drugs. Then, healthy donor PB mononuclear cells 
(PBMCs) incubated as control or with lenalidomide and/or with 
IPH2101 were used as effectors against U266 MM cell targets. 
Lenalidomide increased the specific release, a surrogate for 
cytotoxicity, by around 1.39-fold relative to control (p < 0.01). 
IPH2101 increased the specific release by 1.48-fold (p < 0.01). 
The two drugs combined increased the specific release by 2.09- 
fold relative to control (p < 0.001), which means a significantly 
higher cytotoxic effect than either lenalidomide or IPH2101 
alone. Patient-derived NK cell cytotoxicity against autologous 
MM targets was enhanced by the combination of lenalidomide 
plus IPH2101 (128 ± 9 spots/well) compared with control condi- 
tions (81 ± 7 spots/well). Based on in vitro results, the authors 
  
 
 
 
 
evaluated the efficacy of the anti-KIR 5E6 in lenalidomide pre- 
treated mice. The tumor burden was significantly reduced when 
the combination of 5E6 and lenalidomide was employed, in 
comparison to controls (p < 0.005). These data provide the basis 
for the translation of IPH2101 and lenalidomide combination in 
phase I and II studies. 
 
Daratumumab (DARA) 
Daratumumab is an IgGk monoclonal antibody targeting CD38, 
a cell surface protein that is overexpressed on MM cells (150, 
151). Preclinical studies have shown that DARA induces MM 
cell death through several mechanisms, including complement- 
dependent cytotoxicity (152), ADCC (153), antibody-dependent 
cellular phagocytosis (154), and apoptosis (155). The drug showed 
efficacy as single agent in heavily pretreated MM patients or in 
combination with bortezomib and dexamethasone (156). When 
combined to lenalidomide, the DARA cell-mediated MM cell 
clearance was enhanced due to lenalidomide-dependent NK cell 
activation. In the light of preclinical results of lenalidomide in 
combination with anti-KIR agents, Nijhof et al. hypothesized that 
the NK cell-mediated cytotoxicity induced by DARA could be 
enhanced by anti-KIRs (Figure 2B). The effect could be further 
improved through the association with lenalidomide which 
stimulates the proliferation of NK cells and activates them (157), 
overcoming NK cells depletion induced by DARA itself (158). 
 
elotuzumab 
Initially, Hsi et al. described a humanized antibody, HuLuc63, 
which specifically targeted CS1 (CCND3 subset 1, CRACC, and 
SLAMF7), a cell surface glycoprotein thathadnotpreviously been 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FiGURe 2 | (A) Engagement of self-MHC class I by inhibitory KIR results in dominant-negative signals blocking competing activation responses; lack of MHC class I 
molecules triggers NK cell killing (missing-self recognition); inhibitory KIR blockade by anti-KIR mAbs abrogates KIR-mediated inhibition regardless of MHC class I 
ligand expression on target surface (“induced” missing self). (B) Negative signals transduced by inhibitory KIR antagonize anti-CD38 (DARA)-induced antibody- 
dependent cellular cytotoxicity, potentially dampening NK cytotoxicity to plasma cells; addition of KIR checkpoint inhibitors may potentiate the positive effects of 
DARA on NK cytotoxicity of malignant plasma cells (see also main text). NK, natural killer; KIR, killer cell immunoglobulin-like receptor; MHC, major histocompatibility 
complex; DARA, daratumumab. 
  
 
associated with MM cells. By flow-cytometry, HuLuc63 showed 
specific staining of CD138+ myeloma cells, NK cells, NK-like 
T cells, and CD8+ T cells. HuLuc63 showed significant in vitro 
ADCC against primary myeloma cells as targets and allogeneic 
or autologous NK cells as effectors. The authors concluded that 
HuLuc63 could eliminate MM partly through NK-mediated 
ADCC and targeting CS1 with HuLuc63 could become a novel 
treatment strategy (159). Tai et al. also showed that HuLuc63 was 
effective in inducing ADCC against primary MM cells resistant 
to novel therapies such as bortezomib and HSP90 inhibitor. 
Moreover, pre-treatment with conventional or novel anti-MM 
agents enhanced HuLuc63-induced MM cell lysis (160). Collins 
et al. also hypothesized that elotuzumab may have other 
mechanisms of action. A number of findings clearly suggested 
that elotuzumab may enhance NK cell function beyond ADCC. 
Elotuzumab was shown to induce NK cell activation by binding 
to CS1 which promotes cytotoxicity against CS1+ MM cells but 
not against autologous CS1+ NK cells. Moreover, NK cell activa- 
tion was shown to be dependent on differential expression of the 
signaling intermediary EAT-2 which is present in NK cells but 
absent in primary, human MM cells (161). Therefore, HuLu63 
enhances NK cell cytotoxicity to MM via a dual mechanism 
(Figure 3). The synergy between current anti-CS1 antibody 
elotuzumab, formerly known as HuLuc63, and bortezomib was 
also shown by van Rhee et al. (162). Elotuzumab was approved 
by FDA in 2015 for the treatment of MM, specific for signaling 
lymphocytic activation molecule-F7 (SLAMF7, or CS1) (163). 
As previously mentioned, SLAMF7 is a member of the Ig gene 
superfamily, almost universally expressed (>95%) on the surface 
of marrow MM cells, but not on normal tissues, with restricted 
expression on specific lymphocytes including NK cells. SLAMF7 
determines activating or inhibitory effects on NK cells depending 
on the expression or not of EAT-2, an adapter protein (Figure 3). 
Given that MM cells lack EAT-2, the molecular mechanism by 
which SLAMF7 mediates inhibition in NK cells was investigated 
by Guo et al. It was shown that the inhibitory effects of SLAMF7 
in EAT-2− NK cells was mediated by a mechanism implicating 
lipid phosphatase SHIP-1, Src kinases, and protein tyrosine 
phosphatase CD45. Coupling of SLAMF7 to SHIP-1 was highly 
compromised in MM cells. This correlated with a lack of CD45, 
which is required to activate Src family kinases in hematopoietic 
cells and was needed to initiate SLAMF7 inhibitory signals. This 
defect may explain why elotuzumab eliminates MM cells by an 
indirect mechanism that involves NK cells activation (164, 165). 
An elegant preclinical model clearly showed that elotuzumab 
activates NK cells and promotes myeloma cell death in healthy 
donor PB lymphocyte (PBL)/myeloma cell cocultures (166). 
Moreover, the combination of elotuzumab plus lenalidomide 
demonstrated higher anti-myeloma activity onestablished invivo 
MM xenografts and in in vitro PBL/myeloma cell cocultures than 
either agent alone. In the same study, it was interestingly shown 
that the increased NK cell anti-myeloma functions were also 
due to increased secretion of IL-2 and production of TNF-α that 
combined to enhance NK cell activation and MM cell killing. All 
these findings supported the clinical application of combination 
strategies. Elotuzumab initially showed activity in combination 
with lenalidomide and dexamethasone in a phase I and a phase 
Ib-2 clinical studies in relapsed/refractory MM (167, 168). In a 
subsequet randomized study, patients with relapsed/refractory 
MM received either elotuzumab with lenalidomide and dexa- 
methasone, or lenalidomide and dexamethasone alone. Patients 
who received a combination of elotuzumab, lenalidomide, and 
dexamethasone had a significant relative reduction of 30% in the 
risk of disease progression or death (169). Finally, Jakubowiak 
et al. reported on a phase II study in relapsed/refractory MM 
patients where combined elotuzumab/bortezomib/dexametha- 
sone were compared with bortezomib/dexamethasone until pro- 
gression or unacceptable toxicity. Overall, elotuzumab appeared 
to provide clinical benefit without clinically significant toxicity 
when combined with bortezomib (170). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FiGURe 3 | Elotuzumab activates NK cells via (1) an indirect mechanism, i.e., binding of the extracellular portion of SLAMF7 and recruitment of the EAT-2 adaptor 
protein and (2) a direct mechanism, i.e., antibody-dependent cellular cytotoxicity in response to SLAMF7 tagging on plasma cells. Owing to the absence of EAT-2 in 
plasma cells, elotuzumab engagement does not cause activation of plasma cells. NK, natural killer; EAT-2 Ewing’s sarcoma-associated transcript 2; Fc, fragment 
crystallizable; Fab, fragment antigen binding. 
  
 
iDO inhibitors 
Indoleamine 2,3-dioxygenase plays a pivotal role in the metabolic cascade that converts the essential amino acid l-tryptophan (Trp) into 
l-kynurenine (Kyn). Moreover, IDO has also been shown to be involved in the establishment and maintenance of peripheral 
tolerance. This function may partly be due to IDO1 capacity to restrict the microenvironmental availability of Trp and to increase the 
accumulation of Kyn and derivatives. The expression of IDO on neoplastic lesions may help cancer to escape immunosurveillance. 
IDO inhibitors (i.e., 1-methyl- tryptophan) have therefore become a new class of anti-cancer agents. Current models imply that IDO 
limits both innate and adaptive immunoresponses by depleting immunoeffector cells of Trp (171, 172) and by promoting the 
accumulation of Kyn and its derivatives 3-dydroxykynurenine and 3-hydroxyanthranilic acid (173, 174). These derivatives have been 
shown not only to exert cytostatic and cytotoxic effects on several immunoeffec- tors including CD8 T cells, NK cells, and invariant 
NKT cells (173–175) but also to inhibit TH17 cells and to promote the differentiation of naıve CD4 T cells into Tregs and tolerogenic 
activity of dendritic cells  (174–181).  Interestingly,  Bonanno et al. investigated IDO expression in 25 symptomatic MM and in 7 with 
either MGUS or smoldering MM (182). IDO-driven tryp- tophan breakdown was correlated with the release of hepatocyte growth 
factor (HGF) and with the frequency of Treg cells and NY-ESO-1-specific CD8 T cells. Kyn was increased in 75% of MM patients and 
correlated with the expansion of Treg cells and the contraction of NY-ESO-1-specific CD8 T cells. In vitro, pri- mary MM cells 
promoted the differentiation of allogeneic CD4 T cells into Treg cells and suppressed IFN-γ/IL-2 secretion while preserving IL-4 and 
IL-10 production. Both Treg expansion and inhibition of Th1 differentiation were partly reverted by d,l-1- methyl-tryptophan, an 
inhibitor of IDO. Of note, HGF levels were higher within the marrow microenvironment of patients with IDO (+) MM as compared 
with patients with IDO(−) MM. The antagonism of MET receptor for HGF with SU11274, a MET inhibitor, prevented HGF-induced 
AKT phosphorylation and resulted in reduced IDO protein levels and functional activity. These findings suggest that IDO expression 
may contribute to immunosuppression in patients with MM. IDO inhibitors are currently being tested either as single agent or in 
combination with other anti-cancer drugs in a number of solid tumors even though this class has not yet been evaluated in MM. 
 
NK CeLLS AND THeiR ROLe iN ALLOGRAFTiNG: LeSSONS FROM ACUTe 
LeUKeMiAS 
Some of the most convincing proofs of the potential of NK cells as immunotherapeutic tools derive from evidences accumulated over 
the past two decades in the setting of allogeneic hematopoi- etic stem cell transplantation (allo-HSCT). The interest in NK cell 
immunobiology stemmed mainly from two observations: (a) NK cells are the first lymphocyte subset to recover after transplan- tation, 
often reaching percentages and absolute counts superior to those commonly observed in healthy subjects (183, 184), 
and (b) since KIRs and HLA ligands are encoded on different, independently inherited, chromosomes (chromosome 19 and 6, 
respectively), the KIR gene repertoire transferred from the donor into the host is often different posing the issue whether, and how, an 
efficient NK cell functionality can be achieved (185–187). 
Two hallmark studies came from the Stanford group (188, 
189) where it was demonstrated that after a variable number of months following HLA-matched, KIR-mismatched allo-HSCT, the 
NK cell repertoire is dominated by lymphocytes displaying an immature phenotype (CD56bright and CD94/NKG2A+) and then it 
stabilizes and becomes similar to that of donor origin. Moreover, these studies highlighted significant differences in the repertoire 
recovery kinetics among patients, and clearly correlated impaired NK cell reconstitution with occurrence of post-transplant com- 
plications. The development of a HSCT platform which allowed to safely infuse HLA-haploidentical grafts set the stage for some of 
the most exciting discoveries in transplant biology and trans- lational potential of NK cells. 
Starting from preclinical studies on the tolerogenic potential of “stem cell megadoses” (190), the Perugia team developed a 
protocol which combined a highly immunosuppressive myeloa- blative conditioning regimen with the infusion of high doses of 
extensively T cell-depleted HLA-haploidentical hematopoietic stem cells (HSCs). Full donor engraftment of the partially 
incompatible HSCs was successfully achieved, and despite the absence of post-transplant pharmacological prophylaxis, neither 
acute nor chronic GvHD ensued (191). This elegant and tech- nologically advanced HSCT platform offered the opportunity  to 
investigate the metrics of NK cell reconstitution in a partially HLA-mismatched host and in the absence of confounding factors such 
as alloreactive T cells or immunosuppressive drugs. This highly favorable environment further boosted the early expansion of NK 
cells that had been already described in other transplant settings, and, importantly, led to the appearance of donor-derived NK cells 
with alloreactivity against the host (192). 
Velardi et al. brilliantly described the principles by which NK cell alloreactivity developed  and  designed  an  algorithm to easily 
predict it. Based on this model—later defined as “ligand-ligand” or “KIR-ligand mismatch” model—post-transplant alloreactivity is 
unleashed when the donor carried one or more KIR ligands (i.e., HLA class I alleles encompassing the Bw4, C1, or C2 motifs) absent 
in the host. In this setting, inhibitory KIRs expressed on the surface of donor-derived NK cells—which, in the host, are continuously 
engaged by their respective ligands in the pre-transplant phase—do not find their cognate HLA mol- ecules on host cells and tissues 
leading to a perception of “missing self ” that activates an alloreactive response (193, 194). 
One of the most striking observations by the Perugia group was that NK alloreactivity did not result in clinical GvHD, but, 
conversely, led to a potentially eradicating mechanism of residual leukemic cells reducing relapse incidence and risk of graft failure and 
GvHD (195, 196). Over the following years, several studies confirmed and consolidated the evidence that in T cell-depleted 
  
haploidentical HSCT NK cell alloreactivity represents the main driver of the graft-vs.-leukemia effect and a major predictor of 
overall clinical outcomes in both adults (197–199) and children (200, 201). In addition, these studies were a major drive for the
development of cell therapy protocols in which haploidentical KIR ligand-mismatched NK cells were infused in leukemic patients 
after lymphodepleting chemotherapy with highly prom- ising results (202–204). 
In more recent years, several new platforms of haploidentical HSCT have been developed, mainly with the aim at improving T cell 
immune reconstitution and at reducing post-transplant infectious complications (205). In this “new era,”  studies on  the impact of 
KIR-ligand mismatches on transplant outcomes reported some conflicting results. For instance, it was shown that infusion of 
unmanipulated BM grafts or of donor post-transplant T cell add-backs may mask, or blunt, the effectiveness of NK cell alloreactivity 
(206–208). By contrast, other recent haploidentical HSCT platforms based on the selective depletion of αβ T cells or on the infusion of 
balanced doses of conventional and regula- tory T cells appeared to better preserve the positive effect of KIR ligand mismatches (209, 
210). 
In partially HLA-mismatched unrelated donor HSCT, either from adult volunteers or cord blood (CB) units, the potential role of 
NK alloreactivity has also been a matter of debate. Some studies supported a positive role of KIR ligand mismatches (211–213) and 
others found no significant advantage or even adverse effects (214–216). 
To overcome these inconsistencies, several alternative immu- nogenetic models have been developed to better predict NK cell- 
driven effects on transplant outcomes. In particular, Cooley et al. focused on the donor genetic repertoire and demonstrated in a 
number of independent studies that donors with a KIR gene asset enriched in activating receptors—group B KIR haplotypes—can 
provide a superior relapse-free survival after unrelated HSCT for leukemias (217–219). Another model which takes into account both 
donor activating KIR asset and donor/recipient HLA typing has been proposed and validated by Venstrom et al. In an analysis on more 
than 1,200 unrelated HSCTs, the authors observed that the presence of donor-activating receptor KIR2DS1 and of HLA- C1 ligands 
provided a significant protection from relapse, further enhanced in case of recipient HLA-C1 positivity (220). 
Despite the multiplicity of models proposed over the years in the setting of allo-HSCT, not all the immunogenetic mechanisms that 
regulate NK cell interactions and alloreactivity have fully been understood. However, it is widely assumed that NK cell alloreactivity 
is instrumental in control and eradication of hema- tological malignancies. 
 
NK CeLL THeRAPieS 
expanded NK Cells for MM Treatment 
Expansion of NK cells from PBMC of patients with MM has been achieved using a culture system supplemented with IL-2 and OKT3 
(221). NK cells could be extensively propagated (average 1,625-fold expansion in 20 days) and displayed increased levels of activating 
receptors as well as cytotoxicity to the NK-susceptible K562 line and to autologous MM cells (222). Another NK cell expansion 
strategy for MM immunotherapy is based on the artificial feeder K562 transfected with CD137L and membrane- bound IL-15. This 
technique allowed extensive in vitro NK cellpropagation (average 447-fold, range 20–10,430 on harvest day, i.e., days 10–14). 
Transfer of these cells into a xenogeneic model of high-risk MM resulted in myeloma growth inhibition and protection against 
osteolysis (223). The same group tested the safety, persistence, and activity of expanded NK cells in seven heavily pretreated patients 
with high-risk relapsed myeloma: no serious adverse events related to NK cell infusion was observed. Moreover, the infusion of fresh, 
rather than cryopreserved, cells resulted of fundamental importance for their in vivo expan- sion. Two/seven patients showed some 
responses which lasted for at least 6 months (224). More recently, human studies were performed with allogeneic, KIR ligand-
mismatched NK cells from haploidentical family donors. NK cells were cytotoxic to K562, the myeloma line U266, and recipient 
primary MM cells. Fifty percent of the patients with advanced MM achieved near complete remission when these cells were infused 
prior to autolo- gous SCT (225). Another phase I clinical trial (NCT02481934) evaluated safety and efficacy of multiple infusions of 
activated and expanded NK cells in combination with lenalidomide- or bortezomib-based regimens (226). Five heavily pretreated 
refrac- tory/relapsed patients were enrolled. NK cells were activated and expanded for 3 weeks with K562mb15-41BBL cells. Patients 
received four cycles of new drug-based treatment with two infu- sions of 7.5 × 106/kg NK cells. Four patients showed stable disease 
while on NK cell treatment, two showed a 50% reduction in BM plasma cell infiltration and one obtained a response >1 year. No 
major toxicities were reported. Expanded NK cells showed a highly cytotoxic phenotype and in vitro killing and were detected in both 
BM and PB of treated patients. While efficacy and safety of multiple NK cell infusions need further assessment, these data suggest that 
repeated transfer of in vitro activated and expanded NK cells into MM patients is feasible and may result in clinical benefit when 
combined with anti-myeloma drugs. 
CB NK Cells 
Umbilical CB represents a promising  source  of  allogeneic  NK cells. However, GMP-grade large scale ex vivo expansion is 
indispensable to generate CB-derived NK (CB-NK) cell doses that may be used in the clinical setting. Shah et al. recently described a 
strategy for the expansion of NK cells from cryopreserved CB units (227). By co-culturing for 14 days CB units using artificial 
antigen-presenting feeder cells (aAPC), a highly expanded cell product (average 1,848- and 2,389-fold in 14 days from fresh and 
cryopreserved samples, respectively) of 95% purity for CB-NK cells and less than 1% CD3+ cells was obtained. Despite differences 
in the expression of certain cytotoxicity receptors, aAPC-expanded CB-NK cells were phenotypically very similar to CB-NK cells 
expanded with IL-2 alone. Most importantly, aAPC-expanded CB-NK cells clearly showed cytotoxicity against both in vitro MM 
targets and in vivo anti-myeloma activity in a xenogenic mouse model. The same group investigated the mecha- nisms of CB-NK-
  
mediated cytotoxicity against MM cells (228). Interestingly, a mechanism of transmissible cell death between cells induced by lipid–
protein vesicles transferred from CB-NK to MM cells was described. Moreover, these vesicles were capable of migrating from 
recipient MM cells to neighboring MM cells enhancing cytotoxicity of CB-NK. Altogether, these findings 
supported the development of CB-NK-based cellular therapies for the treatment of MM. An encouraging first-in-human study of CB-
NK cells for MM patients undergoing high dose chemo- therapy and autologous transplantation was recently conducted (229). Patients 
received lenalidomide at a dose of 10 mg from day −8 through −2, standard melphalan at 200 mg/m2 on day 
−7. CB-NK cells were infused on day −5 and the autograft per- formed on day 0. Twelve patients were treated with different dose 
levels. Most patients were heavily pretreated and had high-risk cytogenetics. Overall CB-NK cells with an activated phenotype 
(NKG2D+/NKp30+) were detected in vivo in six patients. Importantly, no signs/symptoms of GVHD were observed.  Eight patients 
achieved at least near complete remission and two additional patients a very good partial response. After a median follow-up of 21 
months, four patients relapsed or experienced progressive disease. 
  
CAR-NK for Myeloma 
The impressive clinical results obtained in patients with B cell malignancies with the infusion of T cells genetically modified to 
express synthetic chimeric antigen receptors (CARs) against the lineage-specific surface antigen CD19 represented a turn- ing point 
in the history of cancer immunotherapy (230–236) Intriguingly, T cells engineered with an anti-CD19 CAR were capable to induce 
complete remission also in a patient with MM. However, given that the large majority of malignant plasma cells do not express 
CD19, studies to understand the mechanism that underlie this unexpected observation are currently in progress (237). More recently, 
a number of CARs have been developed to specifically target surface antigens expressed by pathological plasma cells, including 
CD38 (238, 239), CD138 (240), B cell maturation antigen (241, 242), κ light chains (243), SLAMF7(244), and CD44v6 (245). 
However, despite their tremendous efficacy, CAR-T cells have also raised concerns on their short- and long-term toxicities, in 
particular the development of life- threatening cytokine release syndrome and the risks of prolonged aplasia of the healthy counterparts 
of the target tumor—“off tumor/on target toxicity”—and in case of allogeneic CAR-T cells the development of GvHD (246, 247). 
To address these issues, genetic modifications with CARs of cells belonging to the innate immune system, and of NK cells in 
particular, may yield several potential advantages. For instance, most innate cells recognize and eliminate tumors by stereotyped 
patterns and have been infused into allogeneic recipient without excessive toxicities and with some promising intrinsic antitumor 
efficacy. Moreover, the short-lived persistence of innate immu- nocells in an allogeneic host, considered up to now one of the major 
limitations, may become an added value in case of CARs targeting antigens that are shared with mature cell types for which 
prolonged aplasia may be a concern (i.e., memory B cells, monocytes, or plasma cells) (248, 249). 
Genetic modification of the human NK cell lines NKL and NK-92 by means of a lentiviral vector encoding for anti-SLAMF7 and 
anti-CD138 CARs has proven feasible. This did not sub- stantially modify the expression profile of transduced cells and conferred 
selectivity for the target and the ability to kill human malignant plasma cells both in ex vivo and in an orthotopic xenograft models 
(250, 251). Overall, several steps to optimize and validate CAR-modified NK cells should be taken before their possible clinical use. In 
particular, the choice of the most appro- priate NK cell source to be modified is a matter of intense debate (252). Whether freshly 
isolated NK cells may represent the most physiological choice to achieve sufficient cell doses and transduc- tion efficiency remains 
unknown. Conversely, NK cells expanded from PB or from progenitor cells may be more easily modified even though their 
expression profile and functional competence may be negatively affected by prolonged ex vivo culture. Finally, immortalized human 
NK cell lines, such as NK-92, can be very efficiently transduced and expanded in desired numbers even for “off-the-shelf ” use even 
though their cell surface expression of activating receptors is lower than in freshly isolated or expanded NK cells. Moreover, the need 
to irradiate the cell product before infusion would further limit their in vivo persistence (252, 253). A new modality that exploits the 
combination of the anti-CR38 monoclonal antibody DARA with CD38(−) NK cells  armed with CS1 CAR has very recently been 
described by Wang et al. to treat relapsed MM (254). Given that both CS1 and CD38 
 
  
 
 
 
TABLe 2 | Summary of current treatments with novel agents for multiple myeloma (MM) potentially affecting natural killer (NK) cell activity. 
Agent Mechanism of action on NK cells Clinical trials Reference 
 
PD-1/PD-L1 
checkpoint inhibitors 
 
 
 
 
HLA-KIR checkpoint 
inhibitors 
 
 
 
 
 
 
 
 
 
Daratumumab 
(DARA) 
 
Block of the recognition of PD-L1 by PD-1 on 
NK cells 
PD1 blockade may neutralize competitive negative 
signals resulting in enhanced trafficking, immune 
complex formation, and cytotoxicity of NK cells 
(Figures 1A,B) 
Prevent inhibitory KIR recognition of cognate HLA 
class I ligands 
Blockade of KIR-HLA interactions may neutralize 
negative signals transduced by inhibitory 
KIR2DL1/2/3 (Figure 2A) 
 
 
 
 
 
 
ADCC to CD38+ MM cells 
Cytolytic activity to MM cells triggered by CD16 
signaling upon recognition of antibody tagged 
to CD38 antigen. NK cell-mediated cytotoxicity 
induced by DARA could be enhanced by 
lenalidomide and KIR blockade. 
Other mechanisms: complement-dependent 
cytotoxicity, antibody-dependent cellular 
phagocytosis, and apoptosis (Figure 2B) 
 
Phase I trial of pembrolizumab with lenalidomide and 
dexamethasone. 
Two Phase I trials involving nivolumab showed acceptable 
tolerability. Efficacy assessment of nivolumab, alone or in 
combination is ongoing. 
 
Anti-KIR monoclonal antibody IPH2101 (1-7F9) determined 
the full saturation of NK inhibitory KIR in a phase I trial 
enrolling patients with RR MM. Full KIR occupancy was also 
achieved in a study combining lenalidomide and IPH2101. 
In this study, 5 (33%) patients had a response. In a single 
arm two-stage phase II trial, IPH2101 was employed in 9 
patients with smoldering MM. The study was stopped before 
planned second stage due to lack of patients meeting the 
primary objective (50% decline in M-protein). A phase I study 
combining elotuzumab with lirilumab, a recombinant version 
of IPH2101, is currently in progress 
DARA was tested in combination with bortezomib and 
dexamethasone in RRMM. The primary end point was 
progression-free survival. DARA in combination with 
bortezomib and dexamethasone resulted in a significantly 
longer progression-free survival than bortezomib and 
dexamethasone alone 
 
Benson et al. (125); 
San Miguel et al. (132); 
Suen et al. (133); 
Lesokhin et al. (134) 
 
 
Frohn et al. (136); Benson 
et al. (139); Benson et al. 
(140); Benson et al. (141); 
Korde et al. (142); 
Carlsten et al. (143) 
 
 
 
 
 
 
Palumbo et al. (156) 
Elotuzumab Direct effect: ADCC to MM cells expressing 
SLAMF7 
Indirect effect: activation of SLAMF7+ NK cells 
Dual mechanism of action: (1) NK cell activation 
via SLAMF7 binding and recruitment of the EAT-2 
adaptor proteins; (2) NK-mediated ADCC to 
SLAMF7+ MM cells (Figure 3) 
 
 
 
 
IDO inhibitors Inhibition of l-tryptophan degradation 
Reversal of NK immunosuppression by 
increased availability of l-tryptophan and reduced 
accumulation of l-kyreunine 
Elotuzumab showed activity in combination with lenalidomide 
and dexamethasone in a phase I and a phase IIb-II clinical 
studies in RRMM. In a phase III study, patients with 
RRMM patients were treated with either elotuzumab with 
lenalidomide and dexamethasone, or lenalidomide and 
dexamethasone alone. Patients treated with the combination 
of elotuzumab, lenalidomide, and dexamethasone had a 
significantly reduced risk of disease progression or death. 
In a phase II study in RRMM patients, elotuzumab showed 
clinical benefit without significant toxicity when combined 
with bortezomib 
IDO inhibitors are currently used as single agent or in 
combination in a number of solid tumors. This class has not 
yet been evaluated in clinical trials in myeloma patients 
Lonial et al. (167); 
Lonial et al. (169); 
Jakubowiak et al. (170) 
 
 
 
 
 
 
 
 
Uyttenhove et al. (172); 
Fallarino et al. (173); 
Bonanno et al. (182) 
 
 
PD-1/PD-L1, programmed cell death protein 1/programmed cell death protein ligand 1; KIRs, killer immunoglobulin-like receptors; RR MM, relapsed/refractory MM; ADCC, 
antibody-dependent cellular cytotoxicity; SLAMF7, signaling lymphocytic activation molecule family 7; IDO, indoleamine 2,3-dioxygenase. 
  
ReFeReNCeS 
1. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK. International Myeloma Working 
Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 23(12):2210–21. 
doi:10.1038/ leu.2009.174 
2. Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, et al. Influence of cytogenetics in patients with 
relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 
17p13. Blood (2009) 114(3):522–5. doi:10.1182/blood-2008-12-193458 
3. Cornelissen JJ, Sonneveld P, Schoester M, Raaijmakers HG, Nieuwenhuis HK, Dekker AW, et al. MDR-1 
expressionandresponse to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma 
refractory to alkylat- ing agents. J Clin Oncol (1994) 12(1):115–9. doi:10.1200/JCO.1994.12.1.115 
  
are MM-associated antigens, their simultaneous targeting may prevent progression. The same authors previously showed 
that DARA induces apoptosis in CD38(+) NK cells but not in CD38(−) NK cells. It was then hypothesized that DARA in 
combination with CD38(−) CS1-CAR NK cells may show a synergistic effect and possibly lead to MM eradication. Long-
term follow-up of clinical outcomes of this study are eagerly awaited. 
FUTURe PeRSPeCTiveS 
The potent crosstalk between malignant plasma cells and their BM microenvironment plays a central role in MM progression and 
resistance to current therapies. Novel forms of immunotherapy against MM represent a rapidly developing area in cancer therapy. They 
include treatment strategies that may be delivered either alone or in combination with currently employed therapy lines such as 
IMiDs and proteasome inhibitors as well as newer agents (Table 2). Moreover, immunotherapy may attenuate the systemic toxicity of 
cytotoxic chemotherapy. A robust body of evidence has clearly shown that enhancing host anti-myeloma immunity within the BM 
microenvironment may lead to a more efficient disease control. NK cells play a pivotal role in the intricate network of cells and 
signaling pathways that may prevent immune escape mechanisms. NK cells were clearly shown to have potent in vivo antileukemia 
activity in patients undergoing allografting. Recent observations on NK cell functions in MM have become promis- ing 
immunotherapeutic strategies. New avenues of research have included expansion of NK cells from PB as well as CB, and the 
generations of specific CAR-NK cells against myeloma-specific antigens. Moreover, MM NK cells express PD-1 whereas NK cells 
from healthy individuals do not. This phenotypic characteristic may indicate that immunocheckpoint blockade of NK cells may be 
an area to fully explore given the remarkable results obtained with anti-PD 1 inhibitors in cancer treatment. Altogether, the studies 
reported in this review show that NK cells hold promise in changing the natural course of MM and that may help restore immunity 
to MM and thereby improve survival outcomes. 
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